Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 iito 650x76px
Financing › Details

Phathom Pharmaceuticals–SEVERAL: investment, 201910 IPO $181.7m+$27.2m with 9.56m+1.43m shares common stock at $19/share at Nasdaq Global Select

 

Period Period 2019-10-29
  Predecessor Phathom Pharmaceuticals–SEVERAL: investment, 201905 private crossover financing $90m led by Frazier Healthcare Partners
Organisation Money taker Phathom Pharmaceuticals Inc. (Nasdaq: PHAT)
Products Product gastrointestinal drug
  Product 2 investment banking
     

Phathom Pharmaceuticals, Inc.. (10/29/19). "Press Release: Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares". Buffalo Grove, IL.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of its previously announced initial public offering of 10,997,630 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,434,473 additional shares, at a public offering price of $19.00 per share. Including the option exercise, the gross proceeds to Phathom, before deducting underwriting discounts and commissions and estimated offering expenses, were $209.0 million.

The shares are listed on the Nasdaq Global Select Market under the trading symbol "PHAT."

Goldman Sachs & Co. LLC, Jefferies and Evercore ISI acted as joint book-running managers for the offering. Needham & Company acted as lead manager for the offering.

Registration statements relating to the shares have been filed with the Securities and Exchange Commission and became effective on October 24, 2019. The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.


About Phathom

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases.


David Socks
info@phathompharma.com
1-650-325-5156

Media Contact:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
mikebeyer@sambrown.com

   
Record changed: 2019-11-01

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Phathom Pharmaceuticals Inc. (Nasdaq: PHAT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 iito 650x76px




» top